Form 8-K - Current report:
SEC Accession No. 0001737287-23-000060
Filing Date
2023-06-14
Accepted
2023-06-14 08:04:06
Documents
12
Period of Report
2023-06-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K allo-20230609.htm   iXBRL 8-K 30715
  Complete submission text file 0001737287-23-000060.txt   166452

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20230609.xsd EX-101.SCH 1989
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20230609_lab.xml EX-101.LAB 24139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20230609_pre.xml EX-101.PRE 12595
6 EXTRACTED XBRL INSTANCE DOCUMENT allo-20230609_htm.xml XML 10870
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 231013034
SIC: 2836 Biological Products, (No Diagnostic Substances)